Clinical Trial Update: A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a PRAME-targeted immunotherapy for non-small cell lung cancer after tumor removal.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PRAME-immunotherapy (investigational)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lung Cancer, Non-Small Cell | Phase 2 | Status: COMPLETED | Results posted: 2019-08-28